A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers
- Registration Number
- NCT00411814
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma. Both parts are designed to investigate the safety, tolerability and the way the body absorbs GSK679586A when given by intravenous infusion (through a vein in your arm).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Placebo Placebo Saline Active GSK679586 GSK679586
- Primary Outcome Measures
Name Time Method Safety and tolerability in healthy volunteers.Assessed using clinical safety assessments and blood and urine analysis Throughout the study Safety and tolerability in mild asthmatics.Assessed using clinical safety assessments and blood and urine analysis. Throughout the study
- Secondary Outcome Measures
Name Time Method Blood sampling Throughout the study Effects on blood and lung function. Throughout the study Lung function Throughout the study Plasma levels of GSK679586A to determine pharmacokinetic parameters Throughout the study serum antibodies to GSK679586A Throughout the study
Trial Locations
- Locations (1)
GSK Investigational Site
🇦🇺Melbourne, Victoria, Australia